Zhejiang Medicine (SHA:600216) subsidiary Xincode Bio applied for an initial public offering on the Main Board of the Hong Kong Stock Exchange.
The spinoff and listing are subject to regulatory clearances from Chinese and Hong Kong authorities, according to a Tuesday filing with the Shanghai bourse.
Shares of the drugmaker were down 3% in recent trade.